| MOB1A | |
|---|---|
| Gene Symbol | MOB1A |
| Full Name | MOB Kinase Activator 1A |
| Chromosomal Location | 4q21.1 |
| NCBI Gene ID | [92521](https://www.ncbi.nlm.nih.gov/gene/92521) |
| UniProt ID | [Q9H8S3](https://www.uniprot.org/uniprot/Q9H8S3) |
| Ensembl ID | ENSG00000173482 |
| Associated Diseases | [Alzheimer's Disease](/diseases/alzheimers-disease), [Parkinson's Disease](/diseases/parkinsons-disease), cancer |
MOB1A is a human gene whose product mOB1A (MPS One Binder Kinase Activator 1A) is a key regulatory protein in the Hippo signaling pathway, which controls organ size by regulating cell proliferation, apoptosis, and stem cell self-renewal[1]. MOB1A functions as a co-activator for the NDR family kinases LATS1/2, which phosphorylate and inactivate the transcriptional co-activators YAP and TAZ[2]. Variants in MOB1A have been implicated in Alzheimer's Disease, Parkinson's Disease, Cancer. This page covers the gene's normal function, disease associations, expression patterns, and key research findings relevant to neurodegeneration.
MOB1A (MPS One Binder Kinase Activator 1A) is a key regulatory protein in the Hippo signaling pathway, which controls organ size by regulating cell proliferation, apoptosis, and stem cell self-renewal[1:1]. MOB1A functions as a co-activator for the NDR family kinases LATS1/2, which phosphorylate and inactivate the transcriptional co-activators YAP and TAZ[2:1].
In the Hippo pathway:
The Hippo pathway has been implicated in neuronal survival and neurodegeneration. Dysregulation of YAP/TAZ signaling may contribute to amyloid-beta toxicity and neuronal death in Alzheimer's disease[3].
MOB1A and the Hippo pathway are involved in regulating dopaminergic neuron survival. Alterations in this pathway may affect neurodegeneration in Parkinson's disease[4].
Dysregulation of the Hippo pathway, including MOB1A mutations, is frequently observed in various cancers, where loss of Hippo signaling leads to uncontrolled cell proliferation[5].
MOB1A is ubiquitously expressed with high levels in:
Targeting the Hippo pathway, including MOB1A, is being explored for cancer therapy. In neurodegeneration, understanding Hippo pathway dysregulation may lead to novel therapeutic approaches[6].
Hergovich A. MOB proteins as signalling hubs in cell growth and cell death. Cell Death Discov. 2021. ↩︎ ↩︎
Liu X, Yang N, Figel SA, et al. MOB1A/B are essential for Hippo pathway activation and tumor suppression. Mol Cell Biol. 2013. ↩︎ ↩︎
Huang Z, Wu Q, Guryanova OA, et al. Hippo pathway in neuronal development and neurodegenerative disease. J Mol Neurosci. 2020. ↩︎
Li L, Wang Y, Liu R, et al. Hippo pathway in Parkinson's disease: a new therapeutic target. Cell Mol Neurobiol. 2022. ↩︎
Harvey KF, Zhang X, Thomas DM. The Hippo pathway and human cancer. Nat Rev Cancer. 2013. ↩︎
Ma S, Meng Z, Chen R, Guan KL. The Hippo pathway: biology and pathophysiology. Annu Rev Biochem. 2019. ↩︎